BioNTech SE (BNTX) Gets a Buy from Goldman Sachs
Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $136.00.
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), BioNTech SE (BNTX) and Alnylam Pharma (ALNY)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adaptimmune Therapeutics (ADAP – Research ...
Fierce Biotech2d
BioNTech passes on Autolus' CD19/CD22 CAR-T amid pipeline prioritization
BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to ...
Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen
The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights about 4+ companies and 4+ ...
BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment
BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...
Reuters4d
BioNTech SE
December 13, 2024 US FDA lifts partial clinical hold on BioNTech cancer drug study BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration ...
Morningstar4d
BioNTech SE ADR BNTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
pharmaphorum5d
BioNTech cancer vaccine hits the spot in melanoma
mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...